Nyxoah (NASDAQ:NYXH – Get Free Report) and Establishment Labs (NASDAQ:ESTA – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.
Volatility and Risk
Nyxoah has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for Nyxoah and Establishment Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 1 | 2 | 0 | 2.25 |
| Establishment Labs | 1 | 0 | 8 | 0 | 2.78 |
Valuation & Earnings
This table compares Nyxoah and Establishment Labs”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $21.66 million | 2.70 | -$101.92 million | ($2.52) | -0.60 |
| Establishment Labs | $211.08 million | 10.58 | -$51.06 million | ($1.31) | -57.19 |
Establishment Labs has higher revenue and earnings than Nyxoah. Establishment Labs is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
72.9% of Establishment Labs shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Nyxoah and Establishment Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -443.16% | -178.90% | -81.83% |
| Establishment Labs | -15.82% | -196.69% | -10.73% |
Summary
Establishment Labs beats Nyxoah on 9 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
